High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load

2004 ◽  
Vol 39 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Akihito Tsubota ◽  
Yasuji Arase ◽  
Fumitaka Suzuki ◽  
Yoshiyuki Suzuki ◽  
Norio Akuta ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Japanese Patients ◽  
Baseline Viral Load ◽  
High Dose ◽  
Virus Genotype ◽  
Interferon Alpha 2B ◽  
High Baseline Viral Load ◽  
High Dose Interferon

The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis

2019 ◽  
Vol 26 (3) ◽  
pp. 329-336 ◽  
Author(s):  
Lawrence Serfaty ◽  
Ira Jacobson ◽  
Jürgen Rockstroh ◽  
Frederick L. Altice ◽  
Peggy Hwang ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Baseline Viral Load ◽  
Integrated Analysis ◽  
Virus Genotype ◽  
Genotype 1A

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

2018 ◽  
Vol 49 (3) ◽  
pp. 256-263 ◽  
Author(s):  
Yasue Takeuchi ◽  
Norio Akuta ◽  
Hitomi Sezaki ◽  
Fumitaka Suzuki ◽  
Shunichiro Fujiyama ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Virus Genotype ◽  
Genotype 1B

scholarly journals Early Prediction of Nonresponders to Treatment with Interferon Alpha-2B and Ribavirin in Patients with Chronic Hepatitis C

2003 ◽  
Vol 17 (8) ◽  
pp. 483-487 ◽  
Author(s):  
Louis WC Liu ◽  
George Tomlinson ◽  
Tony Mazzulli ◽  
Alison Murray ◽  
Jenny Heathcote
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Baseline Viral Load ◽  
Hcv Rna ◽  
Interferon Alpha 2B ◽  
Quantitative Measurements ◽  
Treatment Responses

BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection with interferon alpha-2b and ribavirin is costly in terms of side effects, medical resources and drug costs. Furthermore, less than 50% of patients overall have a sustained virological response (SVR).OBJECTIVE: To determine if the log fall in HCV RNA between baseline and week 1 (b-wk1) and between baseline and week 4 (b-wk4) after starting treatment could identify the nonresponders.PATIENTS AND METHODS: Sixty-three patients who had completed a full course of therapy were identified. Quantitative measurements of HCV RNA were analyzed from stored sera, collected prospectively.RESULTS: SVR was achieved in 47.1% and 47.3% of patients in the b-wk1 and b-wk4 groups, respectively. No patients had an SVR with a fall in HCV RNA of less than 0.35 log10and 1.05 log10at week 1 and week 4, respectively. This accounted for 44.4% and 51.7% of the nonresponders in the b-wk1 and b-wk4 groups, respectively. Once the decline in viral load was known, genotype, age, sex and baseline viral load did not provide additional power in predicting treatment responses.CONCLUSION: A fall of 1.05 log10in HCV RNA at week 4 predicts those patients who will not respond, identifying one-half of all nonresponders; this allows therapy to be stopped early, without depriving any patient who would have an SVR from treatment.

Sign in / Sign up

Export Citation Format

Share Document